Selank vs DSIP
Selank is a synthetic heptapeptide developed as an anxiolytic and nootropic agent with immunomodulatory properties. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide originally identified for its ability to promote delta (deep) sleep. Both influence stress and neurological function through distinct mechanisms.
Last updated: 2026-03-13
Selank and DSIP (Delta Sleep-Inducing Peptide) are two neuropeptides that have attracted interest in the context of stress management, anxiety reduction, and sleep regulation. Despite superficial overlaps in their areas of application, they are distinct compounds with different origins, mechanisms, and research histories.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by combining the sequence of tuftsin (an endogenous immunostimulatory tetrapeptide) with a stabilising Pro-Gly-Pro fragment. It has been approved in Russia as an anxiolytic medication and is also researched for nootropic and immunomodulatory effects.
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring nonapeptide first isolated from rabbit brain in 1977. Originally characterised for its ability to induce delta-wave (slow-wave) sleep in animal models, DSIP has since been found to have broader neuromodulatory, stress-protective, and endocrine effects.
**Important Note:** Selank is approved in Russia but not by the MHRA, EMA, or FDA. DSIP is not approved for therapeutic use by any regulatory authority. Both are classified as research peptides in the UK. This comparison is for educational purposes based on published research.
Quick Comparison Table
| Category | Selank | DSIP |
|---|---|---|
| Molecular Type | Synthetic heptapeptide (7 amino acids) | Naturally occurring nonapeptide (9 amino acids) |
| Primary Research Focus | Anxiolytic (anti-anxiety) and nootropic effects | Sleep regulation and stress adaptation |
| Origin | Tuftsin analogue + Pro-Gly-Pro stabiliser (synthetic design) | Naturally occurring — first isolated from rabbit brain |
| Regulatory Status | Approved in Russia (intranasal spray). Not approved in UK/EU/US. | Not approved for therapeutic use anywhere |
| Primary Mechanism | GABA system modulation, BDNF enhancement, monoamine effects | Delta-wave sleep promotion, stress hormone modulation, opioid system interaction |
| Administration | Intranasal spray (approved route in Russia); also studied SC | Subcutaneous/intravenous injection; intranasal (research) |
| Half-Life | Several minutes (native); enhanced by Pro-Gly-Pro modification | ~7-8 minutes (short, but biological effects persist for hours) |
| Immunomodulatory | Yes — significant (tuftsin component) | Limited immune effects reported |
Mechanism of Action Comparison
Selank
Selank — Anxiolytic and Nootropic Neuropeptide:
Selank's anxiolytic and cognitive effects are mediated through multiple neurochemical pathways:
- **GABAergic modulation** — Selank enhances GABAergic neurotransmission, the primary inhibitory system in the brain. It appears to influence GABA-A receptor sensitivity and may modulate benzodiazepine binding sites, producing anxiolytic effects without the sedation, dependence, or cognitive impairment associated with benzodiazepines.
- **BDNF upregulation** — Selank increases expression of brain-derived neurotrophic factor (BDNF), a key neurotrophin supporting neuronal survival, synaptic plasticity, and cognitive function. This neurotrophic effect may underlie both the nootropic and anxiolytic properties.
- **Serotonin metabolism** — Research suggests Selank influences serotonin (5-HT) metabolism, including effects on the enzyme tryptophan hydroxylase (rate-limiting in serotonin synthesis). This may contribute to mood-stabilising effects.
- **Dopamine modulation** — Selank appears to influence dopaminergic signalling, potentially contributing to its effects on motivation, focus, and cognitive processing.
- **Enkephalin stabilisation** — Selank may inhibit enzymes that degrade enkephalins (endogenous opioid peptides), thereby prolonging their anxiolytic and stress-protective effects.
- **Immunomodulation** — The tuftsin component confers significant immunomodulatory properties, including enhancement of phagocytic activity, modulation of cytokine production, and support of innate immune function.
- **Gene expression effects** — Studies have identified over 50 genes whose expression is modulated by Selank, including genes involved in inflammation, neuroplasticity, and neurotransmitter signalling.
DSIP
DSIP — Delta Sleep-Inducing Peptide:
DSIP's mechanisms are less well defined than Selank's, reflecting the complexity of sleep regulation and the peptide's pleiotropic effects:
- **Delta-wave sleep promotion** — DSIP was originally characterised for its ability to promote delta (slow-wave) sleep, the deepest stage of non-REM sleep essential for physical restoration. The exact mechanism remains debated, but may involve modulation of GABAergic and glutamatergic balance in sleep-regulating brain regions.
- **Stress hormone modulation** — DSIP appears to modulate the hypothalamic-pituitary-adrenal (HPA) axis, with reports of reduced ACTH and cortisol levels under stress conditions. This stress-buffering effect may be central to its sleep-promoting and adaptogenic properties.
- **Opioid system interaction** — DSIP interacts with opioid receptors (possibly delta-opioid receptors), which may contribute to its analgesic, sleep-promoting, and stress-protective effects.
- **Monoamine oxidase modulation** — Some research suggests DSIP affects monoamine oxidase (MAO) activity, potentially influencing serotonin, dopamine, and noradrenaline metabolism.
- **Circadian rhythm influence** — DSIP concentrations in the brain show diurnal variation, and the peptide may play a role in circadian rhythm regulation and sleep-wake cycle entrainment.
- **Antioxidant effects** — DSIP has demonstrated antioxidant properties in some studies, potentially providing neuroprotective effects through reduction of oxidative stress.
- **Endocrine effects** — DSIP has been reported to influence the release of several hormones including growth hormone, LH, and melatonin, contributing to its broad neuroendocrine profile.
Benefits Comparison
Selank Unique Benefits
- Anxiolytic effects demonstrated without sedation, dependence, or cognitive impairment (distinct from benzodiazepines)
- Nootropic properties — potential cognitive enhancement including improved memory and attention
- Regulatory approval in Russia as an intranasal medication — validated by a regulatory authority
- Significant immunomodulatory effects through tuftsin component
- BDNF upregulation supporting neuroplasticity and neuroprotection
- Intranasal administration — non-invasive, rapid CNS delivery
- Well-characterised mechanism of action through multiple studies
Shared Benefits
- Stress-protective and adaptogenic properties
- Influence on GABAergic neurotransmission
- Relatively favourable safety profiles in published research
- Both have been researched for anxiety and stress-related conditions
- Non-addictive profiles (contrasting with benzodiazepines or conventional sleep medications)
- Potential neuroprotective effects
DSIP Unique Benefits
- Specific effects on delta (deep) sleep — the most physically restorative sleep stage
- Stress hormone modulation (cortisol/ACTH reduction) under stress conditions
- Naturally occurring peptide — endogenous to the brain
- Potential analgesic effects through opioid system interaction
- Broad neuroendocrine modulation including GH release
- Circadian rhythm support — may help normalise disrupted sleep-wake patterns
- Antioxidant and neuroprotective properties
Research & Evidence
Selank Research
Selank has been extensively studied in Russia, with over 100 publications examining its pharmacology, mechanisms, and clinical effects. Key studies include clinical trials in generalised anxiety disorder, where Selank demonstrated anxiolytic efficacy comparable to medazepam (a benzodiazepine) without the associated sedation or dependence. Gene expression studies have characterised its effects on over 50 genes. The evidence base, while substantial by Russian standards, has limited representation in Western peer-reviewed journals. Independent replication outside Russia is limited.
DSIP Research
DSIP has been researched since its discovery in 1977, with a peak of scientific interest in the 1980s and 1990s. Research has been conducted by multiple groups internationally, though results have been somewhat inconsistent. Some studies confirm sleep-promoting effects, whilst others have failed to replicate findings, leading to controversy about the peptide's efficacy. More consistent data support its stress-protective and endocrine-modulatory effects. Interest waned in the early 2000s but has seen a modest revival in the biohacking and wellness research communities.
Head-to-Head Analysis
No direct comparison. Selank has a more focused and consistent evidence base centred on anxiety, while DSIP's research is broader but more variable in quality and consistency. Selank's regulatory approval in Russia represents a significant evidence threshold that DSIP has not achieved anywhere.
Protocol Comparison
Selank Protocol
Selank (Approved in Russia): Intranasal: 200-300 mcg per nostril, 2-3 times daily (Russian approved protocol). Treatment courses of 14-30 days are typical. Some research has explored subcutaneous injection at similar doses. The intranasal route provides rapid CNS delivery via olfactory and trigeminal pathways.
⚠️ Selank is approved in Russia but NOT in the UK, EU, or US. These are Russian clinical protocols.
DSIP Protocol
DSIP (Research Compound): Research has used doses of 25-50 mcg/kg via subcutaneous or intravenous injection, typically administered in the evening. Some protocols report intranasal administration. Duration of use is variable — from single doses to multi-week courses. No standardised protocol exists as DSIP is not approved for clinical use.
⚠️ DSIP is not approved for therapeutic use anywhere. These are research protocols only.
Combined Use
Theoretical rationale exists for combining Selank (daytime anxiolytic/nootropic) with DSIP (evening sleep promotion) based on their complementary temporal profiles. Selank during the day for anxiety and cognitive support, DSIP in the evening for sleep quality. However, no published research validates this combination. Potential pharmacological interactions are unknown. Combined use is purely speculative.
Safety Profiles
Selank Safety
Selank Safety Profile: Clinical studies and the Russian regulatory approval process have characterised Selank as well tolerated. Reported side effects are minimal: occasional nasal discomfort (intranasal route), very rare reports of mild fatigue, and theoretical allergic reactions. Critically, Selank has NOT been associated with sedation, cognitive impairment, dependence, or withdrawal — distinguishing it from benzodiazepines. No significant adverse events have been reported in published literature. However, long-term safety data outside Russian clinical practice are limited.
DSIP Safety
DSIP Safety Profile: Limited safety data available. Published research generally reports favourable tolerability with few adverse effects. Potential concerns include: mild drowsiness (expected given sleep-promoting action), theoretical effects on endocrine function with chronic use, and unknown long-term safety profile. DSIP's short half-life limits duration of acute effects. The peptide's opioid receptor interaction raises theoretical (but unsubstantiated) concerns about tolerance development. No formal safety evaluation by any major regulatory authority has been conducted.
The Verdict: When to Choose Which?
Choose Selank When:
- Anxiety reduction is the primary goal — Selank has the strongest evidence as a non-sedating anxiolytic peptide
- Cognitive enhancement (nootropic effects) alongside anxiety management is desired
- Immune support is also a consideration — Selank's tuftsin component provides immunomodulatory benefits
- A non-invasive administration route is preferred (intranasal spray)
- A compound with regulatory approval (even if Russian only) provides additional confidence
- BDNF upregulation for neuroplasticity support is valued
Choose DSIP When:
- Improving deep sleep quality (delta-wave sleep) is the primary goal
- Stress-related sleep disruption is the core issue rather than generalised anxiety
- HPA axis modulation (cortisol reduction) under stress conditions is desired
- A naturally occurring endogenous neuropeptide is preferred
- Circadian rhythm disturbance or jet lag recovery is the application context
- Understanding that DSIP's evidence base is less consistent than Selank's
Consider Combining When:
- Theoretical complementary use: Selank during the day for anxiety/cognition, DSIP in the evening for sleep
- No published research supports this combination — safety and interactions are unknown
- Both compounds are non-addictive, reducing theoretical risk of combined dependence
Frequently Asked Questions
Conclusion
Selank and DSIP represent two distinct neuropeptide approaches to stress-related neurological challenges. Selank is the more evidence-based option for anxiety, with Russian regulatory approval, a well-characterised mechanism involving GABA modulation and BDNF enhancement, and a favourable safety profile distinguishing it from benzodiazepines. DSIP offers a unique focus on delta-wave sleep promotion and HPA axis modulation, but its evidence base is less consistent and no regulatory authority has approved it. For anxiety with cognitive concerns, Selank has the stronger rationale. For stress-related sleep disruption, DSIP has theoretical merit but requires further validation. Both are classified as research compounds in the UK and should only be considered under appropriate medical guidance.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Selank nor DSIP is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.